Here, we investigated whether RITA could reactivate the TP53 pathway in medulloblastomas independently of TP53 mutational status, therefore, opening new avenues for the successful treatment of medulloblastomas, regardless of their TP53 mutational status. This evidence concerns the gene TP53 and medulloblastoma.